Global Cardiogenomics Market: Major Trends Reshaping the Future of the Industry

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Cardiogenomics Industry Market Size Be by 2025?
In recent times, the size of the cardiogenomics market has seen a fast-paced expansion. It is projected to rise from a value of $1.50 billion in 2024 to $1.74 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 15.8%. The substantial growth observed in the previous years can be traced back to multiple contributing factors. These include an upsurge in the implementation of polygenic risk scores in cardiac treatments, amplified investments channelized towards genomic research and development, an increase in both, government and private funding in the sector of cardiovascular genomics. Alongside, there has been a prominent surge in interest directed towards preventive cardiology that derives insights from genetics, while an increased emphasis has also been noted on genomic studies conducted on a population-sample scale.

What's the Long-Term Growth Forecast for the Cardiogenomics Market Size Through 2029?
In the upcoming years, the cardiogenomics market is set for rapid expansion, with projections estimating a growth to $3.10 billion in 2029 and a compound annual growth rate (CAGR) of 15.5%. This anticipated growth during the forecast period can be credited to factors such as the escalating demand for customised medicine, a surge in cardiovascular diseases, an increasing trend towards genetic testing for early risk detection, heightened awareness of precision medicine methodologies, and a rise in the availability of direct consumer genetic testing services. Key trends projected to be observed during the forecast period are technology innovations that make accurate cardiac analysis possible, the merging of genomic information with health records to support tailored care, progress in polygenic risk scoring to facilitate advanced disease predictions, enhancements in bioinformatics which accelerate the interpretation of genomic data, and the emergence of technological platforms that cater to high-throughput genetic testing.

View the full report here:
https://www.thebusinessresearchcompany.com/report/cardiogenomics-global-market-report

What Are the Key Growth Drivers Fueling the Cardiogenomics Market Expansion?
The cardiogenomics market is anticipated to grow as personalized medicine becomes more popular. This healthcare model customizes prevention methods, diagnosis and treatments based on a person's unique lifestyle, environmental influences, and genetic makeup. The rise in customized care is a result of advancements in genomics, furnishing a comprehensive understanding of genetic differences to offer more targeted therapies-this enhances patient outcomes and reduces uncertainty in treatments. Cardiogenomics significantly contributes to personalized medicine as it applies genetic data to cater cardiovascular disease prevention, diagnosis, and treatments specific to a person's particular genetic structure. For example, 16 new personalized treatments for rare diseases received FDA approval in 2023, highlighted by the Personalized Medicine Coalition, a non-profit organization situated in the US, in February 2024 - a significant rise from six in 2022. These approved treatments comprised seven cancer medications and three for varying diseases and disorders. Consequently, the rising popularity of personalized medicine fuels the growth of the cardiogenomics market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28156&type=smp

What Are the Key Trends Driving Cardiogenomics Market Growth?
In an attempt to enhance early detection and personalised treatment for cardiovascular-related cancers, leading firms in the cardiogenomics market are concentrating their efforts on developing innovative solutions like oncogenomics. Oncogenomics involves studying the genes related to cancer and their mutations to understand the development and progression of cancer, thus developing targeted therapies and personalised treatment strategies. For example, in April 2025, Fortis Healthcare Ltd., a healthcare corporation from India, established the Fortis Institute of Genomic Medicine in India to foster genetic research and personalised medicine. This effort transforms patient care by allowing early detection of diseases, accurate diagnoses, and personalised treatment in fields such as oncology, cardiology, and neurology. It promotes targeted therapies, enhances treatment results, and encourages preventive care for inherited diseases. This institute's mission is to forward precision medicine with a diverse team and cutting-edge technologies, making healthcare more personalised and efficient for Indian patients.

How Is the Cardiogenomics Market Segmented?
The cardiogenomics market covered in this report is segmented as

1) By Product Type: Testing Kits, Reagents, Instruments, Software, Services
2) By Technology: Next-Generation Sequencing, Polymerase Chain Reaction, Microarray, Other Technologies
3) By Application: Congenital Heart Diseases, Cardiomyopathies, Arrhythmias, Coronary Artery Disease, OtherApplications
4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Research Institutes, Other End Users

Subsegments:
1) By Testing Kits: PCR (Polymerase Chain Reaction) kits, Microarray kits, NGS (Next Generation Sequencing) kits
2) By Reagents: Enzymes, Probes, Buffers
3) By Instruments: Sequencers, Genotyping instruments, Microarray scanners
4) By Software: Data analysis software, Reporting platforms, Bioinformatics tools
5) By Services: Genetic testing services, Counseling services, Data analysis services

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=28156&type=smp

Which Companies Are Leading the Charge in Cardiogenomics Market Innovation?
Major companies operating in the cardiogenomics market are Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings (Labcorp), Quest Diagnostics Incorporated, Illumina Inc., QIAGEN N.V., Myriad Genetics Inc., ARUP Laboratories, BGI Genomics Co. Ltd., Invitae Corporation, GeneDx Inc., Helix OpCo LLC, SOPHiA GENETICS SA, Baylor Genetics, Blueprint Genetics, Novogenia GmbH, Veritas Genetics, Dante Genomics, Gene by Gene Ltd., GENinCode Plc., UAB Cardiogenomics Clinic

Which Regions Are Leading the Global Cardiogenomics Market in Revenue?
North America was the largest region in the cardiogenomics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cardiogenomics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=28156

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.